Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases

Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases

AIM: To assess the risk of severe adverse events (AEs) within 6 months after treatment with biological agents in patients with rheumatic diseases (RD)/MATERIAL AND METHODS: The 6-month open-label trial included 107 patients with rheumatoid arthritis, antineutrophil cytoplasmic antibody-associated va...

Full description

Bibliographic Details
Main Authors: S V Moiseev, P I Novikov, E N Semenkova, L A Strizhakov, S V Guliaev, T N Ianushkevich, N V Nikiforova, A D Meshkov, V V Panasiuk, Iu D Sorokin, M V Taranova, S A Parfenova, L V Dubrovskaia, E S Zhabina, E I Kuznetsova, I A Lopatina, N M Bulanov, N A Mukhin
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2013-05-01
Series:Терапевтический архив
Subjects:
genetically engineered biological agents
rheumatic diseases
vasculitis
rheumatoid arthritis
systemic lupus erythematosus
safety
efficiency
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/31268

Internet

https://ter-arkhiv.ru/0040-3660/article/view/31268

Similar Items